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A natural compound, Flavokawin B, isolated and purified from extract of 
Alpinia zerumbet was investigated for its anti-cancer properties on breast 
cancer cell lines, estrogen dependant MCF-7 and estrogen non-dependant 
MDA-MB-23. Tamoxifen, a non-steroidal anti-estrogen, primarily exploited 
as a drug against hormone-dependent breast cancer, acts as the positive 
control for this study. MCF-IOA, mammary epithelial cells serve as the 
negative control. The cytotoxicities of Flavokawin B and Tamoxifen on 
human breast cells were investigated using the MTT assay. The results 
showed that the ICSo @ S.E.M) value of Flavokawin B on MCF-7 cell line 
was determined to be 1 1.5 Ifi 0.01 5 pM/ml whilst the ICSo with Tarnoxifen 
was at 10.2 + 0.012 W m l .  The ICS0 value of Flavokawin B on MDA-MB- 
23 1 cell line was determined to be 17.5 + 0.0 19 pM/ml whilst the ICS0 value 
of Tamoxifen was at 32.5 2 4.2 pM/ml. The MTT assay results on normal 
epithelial cell line, MCF-1 OA treated with Flavokawin B demonstrated that 
the ICS0 value was 38.0 0.032 pM/ml whereas MCF-1OA treated with 
Tamoxifen had an ICSo value of 28 + 0.021 pM/ml. All values were 
statistically significant (p<0.05), as analysed using one sample T-test. The 
breast cancer cell lines treated at ICS0 concentration of both compounds 
before proceeding using confocal microscopy. There were no significant 
changes observed in the untreated cells. However, apoptotic features were 
that include membrane blebbing and nucleus condensation were evident at 
24 hours. At 48 and 72 hours post treatment, convolution of nuclear 
membrane, destruction of nuclear membrane and fragmentation of the 
nucleus were observed. The TUNEL assay is designed to specifically detect 
and quantify apoptotic cells within a cell population, which primarily 
consists of both apoptotic and non-apoptotic cells. The TUNEL assay 
conducted showed that Flavokawin B induces more apoptosis on MCF-7 
and MDA-MB-23 1 compared to Tamoxifen. In contrast, Flavokawin B has 
lesser lethal effects on MCF-1OA as compared to Tamoxifen. The levels of 
IL-6 secretion in MDA-MB-231 cell line decreased significantly after 
treatment with Flavokawin B. Immunofluorescence studies demonstrated 
that the levels of IL-6 secretion commensurate with the presence of 
membrane bound IL-6r when proliferation of the breast cells was inhibited 
during treatment with both the compounds. The MCF-7 and MDA-MB-23 1 
cell lines were arrested at G1 phase when treated with both Flavokawin B 
and Tamoxifen. This shows that both the treatment follows similar 
mechanism to induce cell phase arrest. In conclusion, it could be confirmed 
that the pure compound Flavokawin B induces apoptosis in MCF-7 and 
MDA-MB-23 1 breast cancer cell lines contributing to the discovery of new 
alternative treatment strategy for breast cancer. 
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Sebatian semulajadi Flavokawin B yang diasingkan dan ditulinkan daripada 
ekstrak Alpinia zerumbet telah dikaji bagi menentukan fungsi sebagai 
antikanser terhadap sel-sel selanjar payudara, samada bergantung kepada 
estrogen MCF-7 atau tidak bergantung kepada estrogen MDA-MB-23 1. 
Tamoxifen, anti-estrogen bukan steroid yang digunakan sebagai drug ke atas 
kanser payudara bergantung kepada estrogen digunakan sebagai kawalan 
positif bagi kajian ini. MCF-1OA yang merupakan sel selanjar epithelial 
payudara digunakan sebagai kawalan negatif. Asai MTT digunakan untuk 
mengkaji kesan sitotoksik rawatan. Keputusan menunjukkan bahawa nilai 
ICso (fS.E.M) untuk rawatan Flavokawin B ke atas sel selanjar MCF-7 
ditentukan sebagai 1 1.5 f 0.0 15 pM/ml sementara nilai ICso bagi rawatan 
Tamoxifen ialah 10.2 f 0.012 pM/ml. Nilai ICsO bagi Flavokawin B ke atas 
sel selanjar MDA-MB-23 1 ditentukan sebagai 17.5 + 0.019 pM/ml 
sementara nilai ICSo bagi rawatan Tamoxifen ialah 32.5 f 4.2 pM/ml. 
Keputusan asai MTT ke atas sel selanjar MCF-1OA menunjukkan nilai ICSO 
bagi Flavokawin B ialah 38.0 + 0.032 pWml sementara nilai ICSo bagi 
rawatan Tamoxifen ialah 28 + 0.021 pWml. Semua nilai ICSo adalah 
signifikan setelah dianalisis menggunakan satu sampel T-test (P <0.05). 
Kajian miksroskop konfokal diteruskan bagi semua sel-sel selanjar dirawat 
dengan Flavokawin B dan Tamoxifen pada kepekatan ICSo masing-masing. 
Tiada perubahan yang signifikan dilihat pada kumpulan kawalan. 
Walaubagaimanapun, ciri-ciri apoptosis telah dilihat seperti pengembungan 
membran dan kondensasi nukleus pada 24 jam. Pada 48 d m  72 jam selepas 
rawatan, konvolusi membran nucleus, pemusnahan d m  fragmentasi 
membran nukleus telah dapat dilihat. Asai TUNEL telah direka untuk 
mengesan dan mengira sel-sel apoptotic dalam satu kumpulan sel yang 
terdiri daripada sel apoptotic dan bukan apoptotic. Berdasarkan keputusan, 
Flavokawin B merangsang lebih banyak apoptosis kepada MCF-7 dan 
MDA-MB-23 1 berbanding dengan rawatan Tamoxifen. 
Walaubagaimanapun, Flavokawin B kurang menghasilkan kesan kematian 
kepada sel selanjar MCF- 1 OA berbanding dengan rawatan Tamoxifen. 
Tahap IL-6 bagi sel selanjar MDA-MB-231 berkurangan selepas dirawat 
dengan Flavokawin B. Kajian imrnunofluorescence menunjukkan bahawa 
tahap rembesan IL-6 bergantung kepada kewujudan IL-6r yang terdapat 
pada membran sel apabila pertumbuhan sel kanser terbantut ketika dirawat 
dengan kedua-dua rawatan tersebut. Sel selanjar MCF-7 dan MDA-MB-23 1 
vii 
ditahan pada fasa G1 apabila dirawat dengan Flavokawin B dan Tamoxifen. 
Ini menunjukkan bahawa kedua-dua rawatan mempunyai mekanisma yang 
sama untuk menahan sel pada fasa tersebut. Kesimpulannya, sebatian 
semulajadi Flavokawin B merangsang apoptosis ke atas sel-sel selanjar 
MCF-7 dan MDA-MB-23 1 membawa kepada penemuan rawatan alternatif 
baru bagi rawatan kanser payudara. 
... 
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CHAPTER 1 
INTRODUCTION 
Cancer is a genetic disease that undergoes clonal evolution of transformed cells 
that arise through the accumulation of mutations; either inherited (germline) or 
acquired (somatic), in critical proto-oncogenes and tumour suppressor genes. 
Carcinogens may be chemical, physical or biological in nature and interacts 
directly or indirectly with DNA and they are ubiquitous. 
In countries such as Europe, USA, Canada, South America, breast cancer 
represents 25-30% of the total incidence of cancers in women and accounts for 
15-18% mortality. The risk of a woman developing breast cancer during her 
lifetime is 1 in 8 in the United States, 1 in 12 in the European Community and 1 
in 80 in Japan. Two-thirds of breast cancers are detected in postmenopausal 
women. Most breast cancers (about 95%), whether in pre- or postmenopausal 
women, are initially hormone-dependent, where the hormone estradiol plays a 
crucial role in their development and progression. The hormone and estrogen 
receptor (ER) complex can mediate the activation of proto-oncogenes and 
oncogenes (Pasqualini, 2004). 
There are several new approaches towards cancer therapy. Breast cancer is 
estrogen responsive and is treated by hormonal therapy using Tamoxifen, an 
anti estrogenic drug. Anti-cancer drugs used in chemotherapy, destroy cancer 
cells and these drugs work by interfering with the ability of cancer cells to 
divide and reproduce itself. The affected cells thus become damaged and 
eventually die. Unfortunately, most chemotherapeutic drugs also affect normal 
cells. The traditional approach in cancer therapy aimed at improving the overall 
survival of metastatic breast cancer include multiple lines of non-cross-resistant 
hormonal therapies, increasing the duration, the dose, and the dose intensity of 
chemotherapy, the use of non-cross-resistant polychemotherapy, and the 
addition of maintenance hormonal therapy. Thus far, the results have not been 
very rewarding despite prolongation of time to progression, improvements in 
overall survival were difficult to obtain, suggesting that these strategies do little 
to alter the natural history of breast cancer once it has metastasized (Awada, et 
al., 2003). 
The scientific evidence that plant based diets, in particular those rich in 
vegetables and fruits, protect against cancers of various sites has been found to 
be strong and consistent (Marchand, 2002). Flavonoids, which are structurally 
similar to estrogens, are able to bind to the estrogen receptor and possess either 
estrogenic or anti-estrogenic activities (Bail, et al., 1998). 
Elimination of tumour cells by the induction of apoptosis has become an 
important and new approach in cancer therapy. Apoptosis known as genetically 
programmed physiological form of cell death is not only involved in the 
development of tumours but also plays an essential role in their treatment 
(Noteborn, et al., 1998). Most of these bioactive substances exert their cancer 
chemotherapeutic activity by blocking cell cycle progression and triggering 
apoptotic cell death. Therefore, induction of apoptosis in tumour cells has 
become an indicator of the tumor treatment response in employing a plant 
derived-bioactive substance to reduce and control human mortality due to 
cancer (Smets, 1994; Paschka,, et al., 1998). 
Recently natural plant researches have been contributing to drug innovation by 
providing plant derived anti-cancer agents. Since, nature has been provided with 
many effective anticancer agents, clinical plant based research has made 
progress in anticancer therapies (De Smet, 1997). 
